



JOHN WINGARD, PhD

Deputy Director, UF Health Cancer Center

**Director, Blood and Marrow Transplant Program, Department of Medicine,
Division of Hematology & Oncology**

**Research Interests: Clinical Trials in Hematologic Malignancies/Blood &
Marrow Transplant; Immunotherapy; Infectious Complications of Cancer;
Cancer Survivorship; Quality of Life Issues**

JOHN WINGARD, MD, is the deputy director of the UF Health Cancer Center and director of the Blood and Marrow Transplant Program in UF's department of medicine's division of hematology and oncology. In his role as deputy director, Dr. Wingard is responsible for developing a strategic plan for the Cancer Center, coordinating membership activities, chairing the Data Integrity and Safety Committee, which monitors clinical trials, and overseeing the center's good manufacturing practices resource to facilitate bringing UF-developed novel cell and drug therapies rapidly to the clinic. He also represents the Cancer Center on multiple institutional committees.

Dr. Wingard was appointed deputy director of the UF Health Cancer Center in 2015. For the preceding four years, he served as its deputy director for research. His research interests include cancer survivorship; hematologic malignancies/blood and marrow transplant; immunotherapy; infection control; and quality of life issues.

Dr. Wingard received his undergraduate training at Yale University, his medical degree from Johns Hopkins University, his residency at University of Tennessee and his oncology fellowship at Johns Hopkins. He began his faculty career at Johns Hopkins, and later joined the faculty at Emory University. Since 1996, he has been on faculty at the University of Florida.

He has been continuously NIH-funded since 1999. He has published more than 400 articles in peer-reviewed journals, 61 book chapters and has edited four books. Dr. Wingard was honored with the University of Florida Research Foundation Professorship, which recognizes faculty members who have distinguished records of research with great promise to continue to make distinctive contributions. In 2018, he was named a Highly Cited Researcher by Clarivate Analytics (top 1 percent most-cited reports in one's field during the year of publication).

Dr. Wingard has held a number of leadership positions in the field of cellular therapy, including co-chair of the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research, chair of the steering committee of the NHLBI/NCI Blood and Marrow Transplant Clinical Trials Network, member of the board of directors of the Foundation for the Accreditation of Cellular Therapies, past president of the American Society of Blood and Marrow Transplantation and member and immediate past chair of the National Marrow Donor Program board of directors.